Strata Critical Medical, Inc. (SRTA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $492.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Strata Critical Medical, Inc. (SRTA) Financials: Revenue, Profit and Cash Flow
Strata Critical Medical reported revenue of $197.14M for the fiscal year ended Dec 31, 2025, down 20.7% from the year before. That year, net income was $41.35M with a net margin of 21.0%, operating cash flow was -$48.91M and free cash flow was -$59.92M. The quarter ended Sep 30, 2026 had revenue of $74.08M and net income of -$7.62M.
Revenue and Margins
The operating margin was -11.3% in the fiscal year ended Dec 2025, the highest of the 7 years shown. Over the 6 years to Dec 2025, revenue grew from $31.20M, a compound annual rate of 36.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $197.14M | -20.7% | 20.9% | -11.3% | 21.0% |
| Dec 2024 | $248.69M | +10.4% | 23.7% | -13.6% | -11.0% |
| Dec 2023 | $225.18M | +54.1% | 18.7% | -30.3% | -24.9% |
| Dec 2022 | $146.12M | +189.2% | 15.2% | -36.6% | -18.7% |
| Dec 2021 | $50.53M | +115.6% | 20.8% | -47.7% | -79.3% |
| Dec 2020 | $23.43M | -24.9% | 9.9% | -44.2% | -43.4% |
| Dec 2019 | $31.20M | N/A | 15.1% | -37.0% | -34.7% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $197.14M | $248.69M | $225.18M | $146.12M | $50.53M | $23.43M | $31.20M |
| Cost of revenue | $156.01M | $189.77M | $183.06M | $123.84M | $40.01M | $21.11M | $26.50M |
| Gross profit | $41.13M | $58.92M | $42.12M | $22.27M | $10.52M | $2.33M | $4.70M |
| Research and development | $3.05M | $3.18M | $4.63M | $5.54M | $1.68M | $861.00K | $751.00K |
| Operating income | -$22.35M | -$33.93M | -$68.12M | -$53.53M | -$24.09M | -$10.36M | -$11.54M |
| Net income | $41.35M | -$27.31M | -$56.08M | -$27.26M | -$40.05M | -$10.16M | -$10.84M |
| EBITDA | -$5.71M | -$21.60M | -$50.43M | -$22.31M | N/A | -$9.83M | -$11.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74.08M | $72.51M | $67.38M | $66.79M | $49.30M | $70.80M | $54.31M | $54.36M | $74.88M | $67.94M | $51.51M | $47.48M |
| Gross profit | $16.82M | $15.21M | $14.12M | $11.67M | $11.61M | $17.74M | $11.98M | $12.59M | $19.84M | $16.35M | $10.14M | $9.01M |
| Operating income | -$3.83M | -$5.41M | -$2.97M | -$6.41M | -$5.62M | -$4.95M | -$7.58M | -$8.37M | -$3.54M | -$12.15M | -$9.87M | -$35.63M |
| Net income | -$7.62M | -$10.52M | $2.15M | -$8.83M | $57.42M | -$3.74M | -$3.49M | -$9.79M | -$1.95M | -$11.33M | -$4.23M | -$33.94M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $652.00K by $30.32M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $325.47M | $256.68M | $294.94M | $325.02M | $335.88M | $17.71M | $277.69M |
| Current assets | $126.19M | $160.74M | $206.26M | $218.13M | $294.94M | $14.38M | $1.43M |
| Cash and equivalents | $30.97M | $18.38M | $27.87M | $41.34M | $2.60M | $12.16M | $1.31M |
| Total liabilities | $46.40M | $34.74M | $60.64M | $50.54M | $44.51M | $6.63M | $272.69M |
| Short-term debt | $652.00K | $3.30M | $4.79M | $3.36M | $438.00K | $1.59M | $231.37K |
| Shareholder equity | $279.07M | $221.94M | $234.30M | $274.49M | $291.37M | $11.08M | $5.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $328.88M | $332.70M | $327.62M | $325.47M | $335.08M | $257.92M | $250.55M | $256.68M | $282.94M | $280.33M | $282.79M | $294.94M |
| Total liabilities | $52.51M | $53.38M | $41.89M | $46.40M | $52.08M | $34.82M | $30.82M | $34.74M | $49.45M | $50.95M | $46.18M | $60.64M |
| Cash and equivalents | $35.14M | $16.32M | $58.72M | $30.97M | $22.75M | $58.75M | $34.83M | $18.38M | $20.03M | $26.31M | $36.76M | $27.87M |
| Shareholder equity | $276.38M | $279.32M | $285.73M | $279.07M | $283.00M | $223.10M | $219.73M | $221.94M | $233.50M | $229.39M | $236.61M | $234.30M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$48.91M | -$2.52M | -$32.35M | -$37.13M | -$15.62M | -$10.82M | -$10.30M |
| Capital expenditures | $11.01M | $32.99M | $2.11M | $730.00K | $297.00K | $377.00K | $854.00K |
| Free cash flow | -$59.92M | -$35.51M | -$34.46M | -$37.86M | -$15.91M | -$11.20M | -$11.16M |
| Investing cash flow | $69.75M | -$1.02M | $17.09M | $79.34M | -$321.34M | -$377.00K | -$1.05M |
| Financing cash flow | -$8.91M | -$5.76M | -$76.00K | -$1.08M | $332.26M | $1.18M | $116.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.46M | $5.69M | $3.56M | -$8.31M | -$31.84M | -$3.06M | -$246.00K | $13.00K | $6.36M | $7.44M | -$15.55M | -$9.32M |
| Capital expenditures | $400.00K | $2.19M | $5.48M | $2.00M | $3.13M | $2.73M | $3.15M | $5.04M | $9.91M | $16.91M | $1.13M | $24.00K |
| Free cash flow | $9.06M | $3.50M | -$1.93M | -$10.31M | -$34.97M | -$5.80M | -$3.39M | -$5.03M | -$3.56M | -$9.46M | -$16.68M | -$9.34M |
Frequently Asked Questions About SRTA
What is Strata Critical Medical's annual revenue?
Strata Critical Medical reported revenue of $197.14M for the fiscal year ended Dec 31, 2025.
How fast is Strata Critical Medical's revenue growing?
Revenue was down 20.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.5%.
Is Strata Critical Medical profitable?
Yes. Strata Critical Medical reported net income of $41.35M for the fiscal year ended Dec 31, 2025, with a net margin of 21.0%.
How much free cash flow does SRTA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.91M minus capital expenditures of $11.01M produced free cash flow of -$59.92M.
How much debt does Strata Critical Medical have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $652.00K and cash and equivalents of $30.97M.
SRTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors